PDCD1 and melanoma: Soluble immune checkpoints may also serve as potent biomarkers of response to PD-1/PD-L1 checkpoint inhibition, as it has been shown that elevated pre-treatment levels of soluble PD-L1 were associated with a progression in melanoma patients treated with PD-1 blockade [71].